Research analysts at HC Wainwright cut their Q1 2025 earnings estimates for Axsome Therapeutics in a research report issued ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Halozyme (HALO – Research Report), Walgreens Boots Alliance ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price increased by equities research analysts at HC ...

Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric ...

Axsome's stock has risen 47% since my August recommendation, driven by FDA approvals and revenue growth. See why I maintain ...

RBC Capital raised the firm’s price target on Axsome Therapeutics (AXSM) to $192 from $143 and keeps an Outperform rating on the shares after ...

Q4 2024 Earnings Call Transcript February 18, 2025 Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Axsome Therapeutics Inc (AXSM) reports significant revenue growth driven by Auvelity and Sunosi, while navigating increased R&D expenses and strategic market challenges.

Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025.